INSM Earnings

INSM reported its earnings on 2026-02-19, showcasing a revenue of 263.84M against an estimate of 263.87M, resulting in a -0.01% surprise. The EPS was -1.54, surpassing the expected -1.07 by -43.93%. The stock experienced a 6.54% price change on the earnings day and a 4.97% change over the next five days, reflecting market reactions to the results.

Following INSM's earnings announcement on 2026-02-19, the stock price moved by 6.54% on the day of the release. Over the subsequent five days, it saw a 4.97% change. Historically, INSM's stock price tends to shift by an average of -1.3% in the 10 days leading up to earnings and 0.04% in the 10 days following, providing insight into potential market.

For 2026/Q1, analysts estimate INSM's annual revenue to reach 191.71M, while the EPS is projected at -1.17. These estimates reflect recent revisions, with revenue estimates revised upward by 1.26% and EPS estimates revised upward by 2.01% over the past three months, indicating analyst expectation in the company's performance.

The correlation between INSM's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were revised upward by 1.26%, while EPS estimates moved revised upward by 2.01%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, INSM's stock price typically moves by -1.3% in the 10 days before its earnings and 0.04% in the 10 days after. For the upcoming 2026/Q1 earnings, analysts expect an EPS of -1.17 and revenue of 191.71M.

The earnings call summary and Q&A section indicate positive sentiment overall. Strong financial metrics and optimistic guidance, especially regarding BRINSUPRI and ARIKAYCE, suggest potential stock price growth. The strategic plan highlights multiple upcoming catalysts, including new drug launches and trials. Management's confidence in market access and revenue opportunities further supports a positive outlook. However, some concerns remain about physician prescribing depth and market access clarity. Despite these, the overall tone is optimistic, warranting a positive sentiment rating.